Innoviva Q3 revenue up 20%, net income surges

Reuters11-06

Innoviva Q3 revenue up 20%, net income surges

Overview

Innoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product sales
Net income for Q3 2025 soars to $89.9 mln from $1.2 mln last year
Company announces $125 mln share repurchase program

Outlook

Company did not provide specific financial guidance for future quarters or fiscal year

Result Drivers

ROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilience
IST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product sales
ZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summer

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Royalty Revenue		$59.9 mln
Q3 Net Income		$89.91 mln
Q3 Pretax Profit		$97.82 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 48.1% above its November 4 closing price of $18.15
The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago

Press Release: ID:nBw2x90rxa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581083917?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 06:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581083917","market":"fut","top_or_hot":-1,"title":"Innoviva Q3 revenue up 20%, net income surges","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Innoviva Q3 revenue up 20%, net income surges</title></head><body><p><span>Overview</span></p><ul><li><p>Innoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product sales</p></li><li><p>Net income for Q3 2025 soars to $89.9 mln from $1.2 mln last year</p></li><li><p>Company announces $125 mln share repurchase program</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or fiscal year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilience</p></li><li><p>IST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product sales</p></li><li><p>ZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summer</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Royalty Revenue</p></td><td></td><td><p>$59.9 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$89.91 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$97.82 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 48.1% above its November 4 closing price of $18.15</p></li><li><p>The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago</p></li></ul><p>Press Release: <span>ID:nBw2x90rxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innoviva Q3 revenue up 20%, net income surges</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnoviva Q3 revenue up 20%, net income surges\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 06:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Innoviva Q3 revenue up 20%, net income surges</title></head><body><p><span>Overview</span></p><ul><li><p>Innoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product sales</p></li><li><p>Net income for Q3 2025 soars to $89.9 mln from $1.2 mln last year</p></li><li><p>Company announces $125 mln share repurchase program</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company did not provide specific financial guidance for future quarters or fiscal year</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilience</p></li><li><p>IST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product sales</p></li><li><p>ZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summer</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Royalty Revenue</p></td><td></td><td><p>$59.9 mln</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>$89.91 mln</p></td><td></td></tr><tr><td><p>Q3 Pretax Profit</p></td><td></td><td><p>$97.82 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the pharmaceuticals peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 48.1% above its November 4 closing price of $18.15</p></li><li><p>The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months ago</p></li></ul><p>Press Release: <span>ID:nBw2x90rxa</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nL1N3WH1FN:1","article_id":"2581083917","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581083917","pubTimestamp":1762381578,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Innoviva Q3 revenue up 20%, net income surgesOverviewInnoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product salesNet income for Q3 2025 soars to $89.9 mln from $1.2 mln last y","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","INVA":"Innoviva, Inc."},"translate_title":"Innoviva第三季度收入增长20%，净利润飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"INVA":0.9},"content_text":"Innoviva Q3 revenue up 20%, net income surgesOverviewInnoviva Q3 2025 total revenue grows 20% yr/yr, driven by royalties and product salesNet income for Q3 2025 soars to $89.9 mln from $1.2 mln last yearCompany announces $125 mln share repurchase programOutlookCompany did not provide specific financial guidance for future quarters or fiscal yearResult DriversROYALTIES GROWTH - Co reports 5% growth in royalties portfolio, highlighting resilienceIST SALES GROWTH - IST achieved 52% yr/yr growth in U.S. net product salesZEVTERA LAUNCH - Early market receptivity for ZEVTERA following U.S. launch over summerKey DetailsMetricBeat/MissActualConsensus EstimateQ3 Royalty Revenue$59.9 mlnQ3 Net Income$89.91 mlnQ3 Pretax Profit$97.82 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 4 \"strong buy\" or \"buy\", no \"hold\" and 1 \"sell\" or \"strong sell\"The average consensus recommendation for the pharmaceuticals peer group is \"buy\"Wall Street's median 12-month price target for Innoviva Inc is $35.00, about 48.1% above its November 4 closing price of $18.15The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 11 three months agoPress Release: ID:nBw2x90rxaFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581083917","isCrawlerRequest":true}